Oruka Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Oruka Therapeutics with a Buy rating and $45 price target Oruka is a clinical stage biotech company developing next-generation biologics aimed at validated targets in inflammation and immunology arenas, the analyst tells investors in a research note. The firm says the company is making validated drugs better, with less frequent dosing.